Candel Therapeutics, Inc. CADL Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s operating cash flow?
- Candel Therapeutics, Inc. (CADL) reported operating cash flow of -$18.04M in Q1 2026.
- How has Candel Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Candel Therapeutics, Inc.'s operating cash flow decreased by 109.3% year-over-year, from -$8.62M to -$18.04M.
- What is the long-term trend for Candel Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s operating cash flow has grown at a 14.6% compound annual growth rate (CAGR), from -$22.22M to -$38.31M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.